

### Medigen Biotechnology Corp.


(3176)

#### **Investor conference**

(2020.12.22)



#### **Business of Medigen Group**





#### Major achievements in 2020

#### Cell Therapy

Natural Killer Cell (Magicell<sup>®</sup>-NK)

3 projects approved by MOHW: our cell therapy technology is approved to be used for cancer treatment in E-Da Cancer hospital, Hualien Tzu Chi Hospital and Chi Mei Hospital, Liouying.

GDT Cell (Magicell<sup>®</sup>-GDT)

First GDT application submitted to MOHW on 2 November 2020.

#### COVID-19 Diagnostic Products

- Nucleic Acid Test Kit: Approved by Taiwan EUA, US EUA and CE-mark
- Antibody Rapid Test: Approved US EUA and CE-mark



#### **Overview of OBP – 301 (oncolytic virus)**

#### Licensing status

- (2019.04.08) Licensed to Chugai Pharmaceutical (Code: 4519); licensed territory includes Japan and Taiwan; optional for other territory excluding China.
- (2020.06.09) Jiangsu Hengrui Medicine Co. returned the rights of OBP-301 in China, Hong Kong and Macau.

#### Current status


- Upfront payment: 550 million yen received
- · First milestone payment: 500 million yen received





#### **Overview of OBP – 301 (oncolytic virus)**

#### Current clinical trial status





#### **Cell therapy allowed under current Special Acts**






#### Introduction of Cell therapy

- Definition: Cells isolated from a subject, purified and expanded *in vitro* to increase cell number and activity, then injected to the subject for the purpose of disease treatment or health enhancement.
- Mechanism : Modulate physiological and biochemical function of human body through cell activity.
- Sources :
  - Autologous cells : cells for treatment come from the same subject
  - Allogeneic cells : cells for treatment come from other subject
- Cell characteristics :
  - Genetically modified cells (such as CAR-T or CAR-NK)
  - Non-genetically modified cells (MSC, IKC, NK, CIK, gamma-delta T, LAK or DC cells)

MSC: Mesenchymal Stem Cell; IKC: Immune Killer Cells; NK: Natural Killer Cells; LAK: Lymphokine Activated Killer Cells; CIK: Cytokine Induced Killer Cells; DC: Dendritic Cells






#### Cell Therapy – Advantages of NK and GDT cell

- With the highest cytotoxic activity against cancer cells
- Can be used off-the-shelf, without inducing GVHD
- Persist for longer period in vivo
- Recognize IPP expressed by some cancer types
- Possess better tumor infiltrating capability

**Cytotoxicity against Cancer cell :** NK >  $\gamma \delta T$  >  $\alpha \beta T$ Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded  $\gamma \delta T$  cells or  $\alpha \beta T$  cells. *International Immunopharmacology.* 2014



#### **Medical institutions collaborating with Medigen**





#### Treatment course of Magicell®-NK



- 6 injections as a basic course
- 12 injections as a comprehensive course
- 1 injection every 1~4 weeks
- 100c.c. iv for 30 min for each injection
- Treatment data will be collected by physicians, including:
  - Image data
  - Life style data
  - Quality of life data
  - Survival data



## Position of Medigen – High quality immune cells with special features

#### Advantages of facilities and services

- Cell processing unit conforming with GTP guidelines
- Integrated clinical trial team and medical advisory team
- Comprehensive patient support and adequate insurance
- Firm and long-term partnership with medical institutions and physicians

#### Advantages of our products

- The only company in Taiwan approved for NK cell therapy
- The only company in Taiwan submitting application for GDT (gamma-delta T) cell therapy
- Of high purity and cytotoxicity





#### **Future Business Targets**

#### GDT cells

To acquire the approval from MOHW for Medigen's GDT cell therapy

#### NK cells

Expand collaboration with more medical institutions to increase the market size

#### Clinical Trials

- Expect to initiate 1~2 clinical trials of NK cells
- Continue OBP-301 clinical development and out-licensing

# MEDIGEN BIOTECHNOLOGY CORP.

